Metabolic Agents

Multum Therapeutic Class Comparison, United States, 2020

Total Prescriptions in (2020)

Drug Name	Total Prescriptions (2020)	Percent Share
Atorvastatin	114,509,815	24.3%
Metformin	92,591,486	19.6%
Simvastatin	36,600,871	7.8%
Rosuvastatin	29,750,488	6.3%
Insulin Glargine	17,973,209	3.8%
Pravastatin	17,549,151	3.7%
Allopurinol	15,303,283	3.2%
Glipizide	13,674,143	2.9%
Insulin Lispro	10,013,738	2.1%
Sitagliptin	9,885,657	2.1%
Insulin Aspart	9,124,642	1.9%
Glimepiride	8,566,883	1.8%
Alendronate	7,923,120	1.7%
Fenofibrate	7,668,856	1.6%
Dulaglutide	7,657,320	1.6%
Lovastatin	7,033,635	1.5%
Ezetimibe	7,029,303	1.5%
Empagliflozin	6,724,609	1.4%
Insulin Detemir	5,164,647	1.1%
Semaglutide	4,827,484	1%
Insulin Degludec	4,600,262	1%
Liraglutide	4,063,184	0.9%
Metformin; Sitagliptin	3,847,463	0.8%
Pioglitazone	3,443,215	0.7%
Gemfibrozil	2,679,954	0.6%
Glyburide	2,417,883	0.5%
Dapagliflozin	2,233,919	0.5%
Insulin Isophane	2,171,842	0.5%
Empagliflozin; Metformin	1,891,720	0.4%
Colchicine	1,876,591	0.4%
Insulin Human; Insulin Isophane Human	1,755,906	0.4%
Icosapent Ethyl	1,238,695	0.3%
Linagliptin	1,168,074	0.2%
Canagliflozin	1,143,266	0.2%
Alogliptin	1,141,082	0.2%
Ibandronate	1,036,005	0.2%
Insulin, Regular, Human	1,012,100	0.2%
Evolocumab	979,183	0.2%
Insulin Aspart Protamine, Human	978,431	0.2%
Ertugliflozin	830,300	0.2%
Niacin	810,390	0.2%
Pitavastatin	763,332	0.2%
Insulin Aspart Protamine, Human; Insulin Aspart, Human	120,285	0%
Glucose	110,886	0%

Total Prescriptions by Drug Over Time

Drug Class Prescribing Trends Over Time

Prescription data source: Medical Expenditure Panel Survey (MEPS) 2013-2020. Agency for Healthcare Research and Quality (AHRQ), Rockville, MD. ClinCalc DrugStats Database version 2022.08. Read more about the ClinCalc DrugStats database.

All ClinCalc DrugStats figures and graphs on this page are licensed under Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0).

Search

Follow Us!

Get Email Updates

New and Popular

Open Menu

Cite This Page

Show AMA citation

Disclaimer - Privacy Policy - Contact Us
Updated Sep 12, 2021

Top